Patents by Inventor Nikolaus Schiering

Nikolaus Schiering has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FACTOR XI ANTIBODIES AND METHODS OF USE
    Publication number: 20240067750
    Abstract: The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: January 20, 2023
    Publication date: February 29, 2024
    Inventors: Jorg EDER, Stefan EWERT, Ulrich HASSIEPEN, Yasser KHDER, Lorenz MAYR, Samu MELKKO, Nikolaus SCHIERING
  • FACTOR XI ANTIBODIES AND METHODS OF USE
    Publication number: 20200115468
    Abstract: The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: September 24, 2019
    Publication date: April 16, 2020
    Inventors: Jorg EDER, Stefan EWERT, Ulrich HASSIEPEN, Yasser KHDER, Lorenz MAYR, Samu MELKKO, Nikolaus SCHIERING
  • Factor XI antibodies and methods of use
    Patent number: 10465011
    Abstract: The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: November 5, 2019
    Assignee: Novartis AG
    Inventors: Jorg Eder, Stefan Ewert, Ulrich Hassiepen, Yasser Khder, Lorenz Mayr, Samu Melkko, Nikolaus Schiering
  • FACTOR XI ANTIBODIES AND METHODS OF USE
    Publication number: 20180355056
    Abstract: The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: June 24, 2016
    Publication date: December 13, 2018
    Applicant: NOVARTIS AG
    Inventors: Jorg EDER, Stefan EWERT, Ulrich HASSIEPEN, Yasser KHDER, Lorenz MAYR, Samu MELKKO, Nikolaus SCHIERING
  • FACTOR XI ANTIBODIES AND METHODS OF USE
    Publication number: 20170022292
    Abstract: The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: June 24, 2016
    Publication date: January 26, 2017
    Applicant: NOVARTIS AG
    Inventors: Jorg EDER, Stefan EWERT, Ulrich HASSIEPEN, Yasser KHDER, Lorenz MAYR, Samu MELKKO, Nikolaus SCHIERING
  • Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
    Patent number: 8877815
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, B, X, m and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of compounds of the invention, and a combination of pharmacologically active agents and a compound of the invention.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: November 4, 2014
    Assignee: Novartis AG
    Inventors: Rajeshri Ganesh Karki, Toshio Kawanami, Gary Michael Ksander, Qian Liu, Muneto Mogi, Nikolaus Schiering, Robert Sun
  • SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP
    Publication number: 20120122764
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, B, X, m and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of compounds of the invention, and a combination of pharmacologically active agents and a compound of the invention.
    Type: Application
    Filed: November 10, 2011
    Publication date: May 17, 2012
    Applicant: NOVARTIS AG
    Inventors: Rajeshri Ganesh KARKI, Toshio KAWANAMI, Gary Michael KSANDER, Qian LIU, Muneto MOGI, Nikolaus SCHIERING, Robert SUN
  • Organic Compounds and their uses
    Publication number: 20100240638
    Abstract: The present application describes macrocyclic compounds of formula (I) with NS3 protease inhibitory activity for treating hepatitis C virus infection.
    Type: Application
    Filed: February 19, 2008
    Publication date: September 23, 2010
    Inventors: Shawn D. Britt, Jiping Fu, David Thomas Parker, Michiael Patane, Parkash Raman, Branko Radetich, Mohindra Seepersaud, Aregahegn Yifru, Rui Zheng, Trixi Brand, Sylvain Cottens, Claus Ehrhardt, Stefan Andreas Randl, Pascal Rigollier, Nikolaus Schiering, Oliver Simic